DOC (4-Chloro-2,5-dimethoxyamphetamine)

Overview

DOC is a synthetic psychedelic in the substituted amphetamine / phenethylamine family and a member of the DOx series (DOM, DOB, DOC, DOI, DON, etc.). It is the 4-chloro analogue of DOM and the de-benzylated cousin of 25C-NBOMe. DOC is characterized by high potency, very long duration, and a reputation for clear, “analytical” headspaces compared to LSD.

• IUPAC name: 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine
• Molecular formula: C₁₁H₁₆ClNO₂
• Molecular weight: ~229.71 g/mol
• CAS Number: 123431-31-2 (hydrochloride: 18717-73-2)
• Class: Psychedelic phenethylamine (DOx series); potent 5-HT₂A agonist

History & Origin

DOC was synthesized and characterized alongside other DOx compounds during the systematic exploration of 2,5-dimethoxy amphetamines in the 1960s–70s. It is documented in Shulgin’s PiHKAL (entry #69), where it is described as producing a clean, long-lasting psychedelic experience with strong visual and cognitive components.

Pharmacology

DOC is a high-affinity agonist at serotonin 5-HT₂A and 5-HT₂C receptors, with the typical amphetamine-class activity at trace amine and monoamine systems. Its pharmacological profile closely parallels DOM and DOI, but the 4-chloro substitution produces distinct subjective effects and slightly different potency.

• Receptor binding: Potent agonist at 5-HT₂A and 5-HT₂C; some activity at 5-HT₂B and adrenergic receptors
• Active oral dose: ~1.5–3 mg (sometimes reported up to 5 mg)
• Onset: 1–2 hours (oral)
• Duration: 12–24 hours (one of the longest in the DOx series)
• Routes: Oral (most common); reported sublingual and insufflated use, though with greater discomfort

Documented Effects (Shulgin, PiHKAL)

At common doses, DOC produces:

• Strong visual hallucinations (geometric patterns, color saturation, motion in static objects)
• Time dilation and altered sense of duration
• A clear, “analytical” or “cerebral” quality, often described as more lucid than LSD
• Physical stimulation and increased heart rate
• Introspection and emotional amplification

At higher doses:

• Confusion, paranoia, and looping thoughts
• Marked body load (jaw tension, nausea, vasoconstriction)
• Difficulty sleeping, sometimes lasting well beyond the primary experience
• In rare cases, seizures or psychotic reactions in predisposed individuals

Safety & Harm Considerations

• Long duration — an episode can last a full day or more, making set/setting/dose errors hard to correct.
• Vasoconstriction — peripheral vasoconstriction with potential for tissue discomfort at higher doses.
• Cardiac considerations — significant 5-HT₂B agonism raises theoretical concerns for valvulopathy with chronic or repeated use.
• Psychological risks — prolonged experiences can trigger anxiety, panic, or persisting psychological distress, especially in unprepared users.
• Drug interactions — dangerous with MAOIs, SSRIs, SNRIs, tramadol, and other serotonergic substances (serotonin syndrome risk).
• Tolerance — develops rapidly; full cross-tolerance with other 5-HT₂A agonists (DOM, DOI, LSD) resets within ~5–7 days.
• Misrepresentation — like other potent DOx and NBOMe compounds, DOC has occasionally been found on blotter paper sold as LSD, producing unexpectedly intense experiences